A Study of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The ultimate goal of the study is to identify potential biomarkers, immune gene expression
signatures, and co-stimulatory pathways that may be used to understand the effect of immune
checkpoint inhibitors on gynecologic cancers.